Skip to main content
ACRV
NASDAQ Life Sciences

Acrivon Details ACR-525 JAK1 Data and EoE Phase 2 Plan at R&D Event

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.6
Mkt Cap
$67.28M
52W Low
$1.27
52W High
$3.56
52W Position info
26% above low
Off High info
55% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ACRV sits 26% above its 52-week low of $1.27 on light trading volume (0.3× avg).

Summary

Acrivon presented the first detailed data package on ACR-525, the oral JAK1 inhibitor it acquired on November 6, claiming 49x biochemical JAK1/JAK2 selectivity, clean Phase 1 healthy-volunteer results and a Phase 2-ready plan in eosinophilic esophagitis. The deck adds scientific substance to a four-day-old acquisition but no new timeline or spending guidance.


Key Events · Product Development and Regulatory · ACRV

  • ACR-525 Data Package Unveiled

    Acrivon detailed ACR-525, the oral JAK1 inhibitor acquired from Aqilion on 2026-11-06, reporting 49x biochemical JAK1/JAK2 selectivity (JAK1 IC50 3.5 nM vs JAK2 171 nM) and >120x cellular selectivity.

  • Phase 1 Safety and PK Support Once-Daily Dosing

    Phase 1 healthy-volunteer studies showed dose-proportional PK with T1/2 ~12h, a dose-dependent CXCL10 decrease, no SAEs and limited reticulocyte effect, consistent with minimal JAK2 inhibition.

  • EoE Chosen as First Indication

    ACR-525 is Phase 2-ready in eosinophilic esophagitis, wholly-owned with no milestone or royalty obligations and composition-of-matter protection to 2038; the company did not state a Phase 2 start date.

  • Differentiation Claims vs Approved JAK Inhibitors

    AP3 profiling indicates non-SMAD TGF-beta/STAT3 pS727 suppression (potential antifibrotic effect) and no pro-apoptotic BAD S134 phosphorylation, unlike brepocitinib and londamocitinib.


Analysis · ACRV · Life Sciences

Acrivon used a two-hour KOL webcast to put real data behind the ACR-525 asset it bought four days ago. The pitch is selectivity: ACR-525 is 49x selective for JAK1 over JAK2 biochemically (3.5 nM vs 171 nM) and more than 120x in cells, which the company argues could mean JAK1-driven efficacy with less JAK2-related toxicity. Phase 1 healthy-volunteer data showed dose-proportional exposure, a ~12-hour half-life supporting once-daily oral dosing, a dose-dependent drop in CXCL10, no serious adverse events and limited reticulocyte impact. Management also flagged non-SMAD TGF-beta/STAT3 suppression as a possible antifibrotic edge and the absence of pro-apoptotic BAD signaling as a safety differentiator versus brepocitinib and londamocitinib. The commercial case rests on EoE having no approved oral advanced small molecule — only injected dupilumab as a step-up biologic — in a US population the deck puts above 500,000. Nothing here changes the cash story: the last 10-Q showed $90.0M funding operations into Q4 2027, and the company gave no timeline for an EoE Phase 2 start, so the next hard datapoint is that trial, not this presentation.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACRV was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACRV - Latest Insights

ACRV
Nov 06, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.57 info
Change: -$0.030 (-2%) info
Market Cap: $67.28M info
ACRV
Nov 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.57
Real-time Price: $1.57 info
Change: $0 (0%) info
Market Cap: $67.28M info
ACRV
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.57 info
Change: -$0.150 (-9%) info
Market Cap: $67.28M info
ACRV
Aug 05, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.57
Real-time Price: $1.57 info
Change: $0 (0%) info
Market Cap: $67.28M info
ACRV
Jun 17, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.52
Real-time Price: $1.57 info
Change: +$0.050 (+3%) info
Market Cap: $67.28M info